Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.
Metrics to compare | 6492 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6492PeersSector | |
---|---|---|---|---|
P/E Ratio | −11.1x | −24.4x | −0.5x | |
PEG Ratio | 5.59 | 0.02 | 0.00 | |
Price/Book | 3.3x | 2.7x | 2.6x | |
Price / LTM Sales | 3,228.5x | 30.1x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.5% | |
Fair Value Upside | Unlock | −17.4% | 6.9% | Unlock |